{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:18:19Z","timestamp":1770430699687,"version":"3.49.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aims of this study were to assess whether dihydrohonokiol, 3\u2032-(2-propenyl)-5-propyl-(1,1\u2032-biphenyl)-2,4\u2032-diol (DHH-B), a potent anxiolytic compound, developed benzodiazepine-like side effects.<\/jats:p>\n               <jats:p>A 1 mgkg\u22121 dose of diazepam, almost equivalent to the minimum dose for the anxiolytic effect, disrupted the traction performance, potentiated hexobarbital-induced sleeping and impaired learning and memory performance. DHH-B, even at a dose of 1 mg kg\u22121 (i.e. five times higher than the minimum dose for significant anxiolytic effect) neither developed diazepam-like side effects nor enhanced the side effects of diazepam. Rather, the potentiation by diazepam of hexobarbital-induced sleeping was reduced by 1 mg kg\u22121 DHH-B. Furthermore, mice treated with 10 daily administrations of 1 and 5 mg kg\u22121 diazepam, but not 0.2\u20135 mg kg\u22121 DHH-B, showed precipitated withdrawal symptoms characterized by hyper-reactivity, tremor and tail-flick reaction when they were challenged with flumazenil (10 mg kg\u22121 i.p.).<\/jats:p>\n               <jats:p>These results suggest that, unlike the benzodiazepine anxiolytic diazepam, DHH-B is less likely to induce motor dysfunction, central depression, amnesia or physical dependence at the effective dose required for the anxiolytic effect.<\/jats:p>","DOI":"10.1211\/0022357001774741","type":"journal-article","created":{"date-parts":[[2003,7,18]],"date-time":"2003-07-18T23:43:52Z","timestamp":1058571832000},"page":"1017-1022","source":"Crossref","is-referenced-by-count":2,"title":["Does Dihydrohonokiol, a Potent Anxiolytic Compound, Result in the Development of Benzodiazepine-like Side Effects?"],"prefix":"10.1093","volume":"52","author":[{"given":"Hisashi","family":"Kuribara","sequence":"first","affiliation":[{"name":"Department of Neuropsychopharmacology (Tsumura), Gunma University School of Medicine , 3\u201339-22 Showa-machi, Maebashi, Gunma 371\u20138511,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiko","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Neuropsychopharmacology (Tsumura), Gunma University School of Medicine , 3\u201339-22 Showa-machi, Maebashi, Gunma 371\u20138511,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Neuropsychopharmacology (Tsumura), Gunma University School of Medicine , 3\u201339-22 Showa-machi, Maebashi, Gunma 371\u20138511,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2000,8,1]]},"reference":[{"key":"2024103110050737700_cit1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/BF01972300","article-title":"Use of specific benzodiazepine antagonist, Ro 15-1788, in studies of physiological dependence on benzodiazepines","volume":"38","author":"Cumin","year":"1982","journal-title":"Experientia"},{"key":"2024103110050737700_cit2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0165-6147(92)90027-4","article-title":"Multiple benzodiazepine receptors: no reason for anxiety","volume":"13","author":"Doble","year":"1992","journal-title":"Trends Pharmacol. Sci."},{"key":"2024103110050737700_cit3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0301-0082(93)90047-V","article-title":"The rapidly expanding range of neuronal benzodiazepine receptor ligands","volume":"40","author":"Gardner","year":"1993","journal-title":"Proc. Neurobiol."},{"key":"2024103110050737700_cit4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0165-6147(90)90126-S","article-title":"Novel anxiolytics that act as partial agonists at benzodiazepine receptors","volume":"11","author":"Haefely","year":"1990","journal-title":"Trends Pharmacol. Sci."},{"key":"2024103110050737700_cit5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02253713","article-title":"Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock","volume":"101","author":"Itoh","year":"1990","journal-title":"Psychopharmacology"},{"key":"2024103110050737700_cit6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0014-2999(91)90125-A","article-title":"Utility of an elevated plus maze for dissociation of amnesic and behavioral effects of drugs in mice","volume":"194","author":"Itoh","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"2024103110050737700_cit7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0376-8716(95)01138-O","article-title":"Flunitrazepam and nordiazepam slowly released from silastic capsules induce physical dependence in rats","volume":"39","author":"Jing","year":"1995","journal-title":"Drug Alcohol Depend."},{"key":"2024103110050737700_cit8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1254\/jjp.27.117","article-title":"Effects of central depressants on rota-rod and traction performances in mice","volume":"27","author":"Kuribara","year":"1977","journal-title":"Jpn. J. Pharmacol."},{"key":"2024103110050737700_cit9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.2042-7158.1998.tb07146.x","article-title":"Behavioral pharmacological characteristics of honokiol, as an anxiolytic agent in extracts of Magnolia bark, evaluated by means of an elevated plus-maze in mice","volume":"50","author":"Kuribara","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"2024103110050737700_cit10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1211\/0022357991772008","article-title":"Honokiol, a putative anxiolytic agent extracted from magnolia bark, has no diazepine-like side effects in mice","volume":"51","author":"Kuribara","year":"1999","journal-title":"J. Pharm. Pharmacol."},{"key":"2024103110050737700_cit11","article-title":"Comparative assessment of anxiolytic effect of honokiol and the derivatives following an improved elevated plus-maze test in mice","author":"Kuribara","year":"2000","journal-title":"Pharmacol. Biochem. Behav."},{"key":"2024103110050737700_cit12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0028-3908(91)90021-3","article-title":"Effects of benzodiazepine receptor antagonist, flumazenil, on antinociceptive and behavioural responses to the elevated plus-maze in mice","volume":"30","author":"Lee","year":"1991","journal-title":"Neuropharmacology"},{"key":"2024103110050737700_cit13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0028-3908(94)00158-O","article-title":"GABAA\/ benzodiazepine receptor heterogeneity: neuropharmacological implications","volume":"34","author":"L\u00fcddens","year":"1995","journal-title":"Neuropharmacology"},{"key":"2024103110050737700_cit14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0091-3057(93)90562-8","article-title":"Precipitated abstinence in the diazepam dependent rat","volume":"46","author":"Martin","year":"1993","journal-title":"Pharmacol. Biochem. Behav."},{"key":"2024103110050737700_cit15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0091-3057(92)90127-2","article-title":"Physical dependence on diazepam: precipitation of abstinence syndromes by peripheral and central benzodiazepine receptor antagonists","volume":"41","author":"Martinez","year":"1992","journal-title":"Pharmacol. Biochem. Behav."},{"key":"2024103110050737700_cit16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1021\/np9702446","article-title":"Identification of magnolol and honokiol as anxiolytic agents in extracts of Saiboku-to, an oriental herbal medicine","volume":"61","author":"Maruyama","year":"1998","journal-title":"J. Nat. Prod."},{"key":"2024103110050737700_cit17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0024-3205(82)90698-1","article-title":"The effect of benzodiazepine antagonist, Ro 15-1788, in diazepam dependent rat","volume":"31","author":"McNicholas","year":"1982","journal-title":"Life Sci."},{"key":"2024103110050737700_cit18","first-page":"1349","article-title":"Issues in the long-term treatment of anxiety disorders","volume-title":"Psychopharmacology: the Fourth Generation of Progress","author":"Schweizer","year":"1995"},{"key":"2024103110050737700_cit19","first-page":"1341","article-title":"The pharmacotherapy of acute anxiety","volume-title":"Psychopharmacology: the Fourth Generation of Progress","author":"Shader","year":"1995"},{"key":"2024103110050737700_cit20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0920-1211(88)90004-6","article-title":"Ro 15-1788-induced seizures in rats continually exposed to diazepam for prolonged periods","volume":"2","author":"Wilson","year":"1988","journal-title":"Epilepsy Res."},{"key":"2024103110050737700_cit21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF02245824","article-title":"Current benzodiazepine issues","volume":"118","author":"Woods","year":"1995","journal-title":"Psychopharmacology"},{"key":"2024103110050737700_cit22","first-page":"151","article-title":"Benzodiazepines: use, abuse, and consequences","volume":"44","author":"Woods","year":"1992","journal-title":"Pharmacol. Rev."},{"key":"2024103110050737700_cit23","first-page":"1777","article-title":"Abuse and therapeutic use of benzodiazepines and benzodiazepine-like drugs","volume-title":"Psychopharmacology: the Fourth Generation of Progress","author":"Woods","year":"1995"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1211%2F0022357001774741","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/52\/8\/1017\/60263169\/0022357001774741.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/52\/8\/1017\/60263169\/0022357001774741.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:41:19Z","timestamp":1730371279000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/52\/8\/1017\/6157600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8,1]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2000,8,1]]},"published-print":{"date-parts":[[2000,8,1]]}},"URL":"https:\/\/doi.org\/10.1211\/0022357001774741","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2000,8]]},"published":{"date-parts":[[2000,8,1]]}}}